Overview

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of the immunotherapy drugs, CT-011 and rituximab, can help control follicular lymphoma. The safety of this drug combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
CureTech Ltd
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Pidilizumab
Rituximab